Zourunan Wart Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, “cauliflower-like” appearance on the surface, making them easily recognizable. Plantar warts are specifically located on the bottom of the foot and are distinguished by tenderness and disruption of the footprint pattern.

Dosage and Administration

The affected area should be washed thoroughly, and warts may be soaked in warm water for approximately 5 minutes to facilitate treatment. A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. After application, the treated area should be allowed to dry.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition. The product should not be applied to moles, birthmarks, warts with hair, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, individuals with diabetes or poor blood circulation should not use this product, as it may pose increased risks of adverse effects in these populations.

Contact with the eyes must be avoided; in the event of exposure, the eyes should be flushed with water for 15 minutes. Inhalation of vapors should also be avoided to prevent respiratory irritation.

Warnings and Precautions

For external use only; this product is flammable and must be kept away from fire and flame.

It is imperative that this product not be applied to irritated skin or any area that is infected or reddened. Additionally, it should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation, as the use of this product may pose additional risks.

In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended without delay.

Should discomfort persist after application, it is essential to discontinue use and consult a healthcare professional for further evaluation and guidance.

Side Effects

Patients should be aware that the product is for external use only and is flammable; it should be kept away from fire and flame. In the event that discomfort persists, patients are advised to stop using the product and consult a healthcare professional.

It is important for patients to seek medical advice if discomfort continues after use, as this may indicate a need for further evaluation or alternative treatment options.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Zourunan Wart Remover (wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of ZOURUNAN WART REMOVER during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks to fetal outcomes are not established, and therefore, the use of this product in pregnant women should be approached with caution. Women of childbearing potential should be advised to discuss their pregnancy status and any potential risks with their healthcare provider before using this medication.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects during lactation. Healthcare professionals should consider the lack of data when advising lactating mothers about the use of this medication. It is recommended to weigh the potential benefits against any unknown risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse effects that may arise. In the event of suspected overdosage, it is recommended to initiate supportive care and symptomatic treatment as necessary.

Healthcare providers should consider contacting a poison control center for guidance on management strategies tailored to the specific situation. Continuous assessment of the patient's clinical status is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is crucial to emphasize the importance of acting quickly in such situations.

Patients should be instructed to avoid contact with their eyes. In the event that the product does come into contact with the eyes, they should flush the affected area with water for at least 15 minutes to minimize potential harm.

Additionally, healthcare providers should caution patients against inhaling vapors from the product, as this may pose health risks.

Finally, it is important to remind patients to cap the product tightly after use and to store it at room temperature, away from heat sources, to ensure its stability and safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37℃ (99℉). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Zourunan Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)